Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q4 FY24
Investor Presentation
Q3 FY24
Investor Presentation
Q2 FY24
Investor Presentation
Q4 FY23
Investor Presentation
Q3 FY21
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
868.00 | 9,676 Cr | 55.96 | 10.95 | 0.00 | 19.57 | 22.16 | 14.83 | ||
1045.20 | 9,623 Cr | 17.30 | 3.10 | 0.48 | 17.90 | 17.30 | 8.29 | ||
3370.70 | 8,112 Cr | 19.63 | 9.43 | 3.49 | 42.11 | 52.41 | 25.64 | ||
569.15 | 7,075 Cr | 31.89 | 15.15 | 0.79 | 47.50 | 52.11 | 32.88 | ||
215.00 | 6,974 Cr | 4.49 | 5.21 | 0.00 | 116.01 | 80.89 | 71.55 | ||
845.50 | 6,799 Cr | 32.51 | 5.68 | 0.12 | 17.46 | 23.00 | 15.41 | ||
417.80 | 6,794 Cr | 24.14 | 2.73 | 1.20 | 11.32 | 15.18 | 9.64 | ||
| Median: 7 Co. | — | 845.50 | 7,075 Cr | 24.14 | 5.68 | 0.48 | 19.57 | 23.00 | 15.41 |
Upcoming Result Date: Aug 03, 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Sanofi India Ltd (SANOFI) is currently trading at 3,377.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Sanofi India Limited is a listed pharmaceutical company focused on manufacturing and marketing prescription medicines in India, with a strategic emphasis on diabetes care (insulin portfolio) and distribution partnerships for cardiovascular, CNS and oral anti‑diabetic categories; it operates manufacturing sites (notably Goa) and sells through independent distributors across domestic and select export markets. The company completed a pivotal transformation in 2025: refocusing on insulin, launching a partnership model for legacy brands, and reorganizing around digital and AI‑enabled customer engagement, which management cites as the foundation for sustainable, profitable growth even as transitional effects impacted reported revenue and segmental comparability. Financially the year shows mixed signals: domestic sales were essentially flat (+1% FY), diabetes insulin domestic volumes grew +6% and Q4 diabetes grew +11%, but exports plunged (-40% FY) driven by Ankleshwar divestment and partnership phasing, while operating expenses were cut ~17% year‑on‑year supporting a marginal PBT increase of +1% for FY25. Sanofi India retains market leadership in basal insulin (Lantus ~31% market share) and is investing to scale Soliqua and Toujeo via private and public sector access, while RWE and clinical work (LANDMARC, Soliqua Phase IV) provide evidence and KOL advocacy to support uptake and formulary inclusion across public programs and tier‑2/3 outreach. Corporate returns remain shareholder friendly: management proposed a dividend increase of ~5% versus prior year with EPS of INR 142 and a high payout ratio (~87%), reflecting a capital distribution stance supported by operational efficiency despite transitional top‑line headwinds.
Over the past 52 weeks, Sanofi India Ltd has traded between a low of ₹3,057.60 and a high of ₹5,922.45. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Sanofi India Ltd has a market capitalization of approximately 8,111.74. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Sanofi India Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 19.63 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 8,111.74 Cr, Sanofi India Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Sanofi India Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Sanofi India Ltd is 19.63. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Sanofi India reported standalone net sales of Rs 419.80 crore for the quarter ended December 2025.
Sanofi India Limited is a listed pharmaceutical company focused on manufacturing and marketing prescription medicines in India, with a strategic emphasis on diabetes care (insulin portfolio) and distribution partnerships for cardiovascular, CNS and oral anti‑diabetic categories; it operates manufacturing sites (notably Goa) and sells through independent distributors across domestic and select export markets.
The company completed a pivotal transformation in 2025: refocusing on insulin, launching a partnership model for legacy brands, and reorganizing around digital and AI‑enabled customer engagement, which management cites as the foundation for sustainable, profitable growth even as transitional effects impacted reported revenue and segmental comparability.
Financially the year shows mixed signals: domestic sales were essentially flat (+1% FY), diabetes insulin domestic volumes grew +6% and Q4 diabetes grew +11%, but exports plunged (-40% FY) driven by Ankleshwar divestment and partnership phasing, while operating expenses were cut ~17% year‑on‑year supporting a marginal PBT increase of +1% for FY25.
Sanofi India retains market leadership in basal insulin (Lantus ~31% market share) and is investing to scale Soliqua and Toujeo via private and public sector access, while RWE and clinical work (LANDMARC, Soliqua Phase IV) provide evidence and KOL advocacy to support uptake and formulary inclusion across public programs and tier‑2/3 outreach.
Corporate returns remain shareholder friendly: management proposed a dividend increase of ~5% versus prior year with EPS of INR 142 and a high payout ratio (~87%), reflecting a capital distribution stance supported by operational efficiency despite transitional top‑line headwinds.
Pharmaceuticals & Biotechnology
Pharmaceuticals
8,130 Cr
Low Risk
19.7
37.2
-0.6
9.4
5,922.45
3,057.60
Sales CAGR
Profit CAGR
ROE
ROCE
Bearish
5
Neutral
8
Bullish
1
Bearish
29
Neutral
8
Bullish
9
Bearish
24
Neutral
0
Bullish
8
Earnings Call/Transcript
Sanofi India to hold an investor/analyst call on 2026-08-05 at 16:00 IST to discuss unaudited financial results for the quarter and half year ended 30 June 2026; pre-registration required.
Earnings Call/Transcript
Sanofi India Ltd will hold an investor/analyst call on 2026-08-05 from 16:00 to 17:00 IST to discuss unaudited Q1 and H1 financial results for the period ended 30 June 2026. Pre-registration required.
Change in Directors/KMP
Sanofi India Ltd: Whole Time Director, CFO and KMP Mr. Rachid Ayari will step down effective close of business hours on 2026-09-30; company to identify and announce a successor in due course.
Change in Directors/KMP
Sanofi India Ltd announced that Whole Time Director & CFO Mr. Rachid Ayari will step down effective close of business on 2026-09-30; company to appoint a successor in due course.
Change in Directors/KMP
Sanofi India Ltd: Whole Time Director and CFO Mr. Rachid Ayari will step down effective close of business on 2026-09-30; company to identify and announce a successor in due course.
Change in Directors/KMP
Sanofi India Ltd announced that Whole Time Director and CFO Mr. Rachid Ayari will step down effective close of business on 2026-09-30 as he transitions to another role within the Sanofi group; a replacement will be identified.
